VictoryShares US 500 Enhanced Volatility Wtd ETFCFO
CFO
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
0.61% more ownership
Funds ownership: 50.74% [Q3] → 51.35% (+0.61%) [Q4]
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0% less capital invested
Capital invested by funds: $239M [Q3] → $239M (-$46.3K) [Q4]
4% less funds holding
Funds holding: 68 [Q3] → 65 (-3) [Q4]
50% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 32
Research analyst outlook
We haven’t received any recent analyst ratings for CFO.
Financial journalist opinion
Neutral
Business Wire
3 months ago
Kashiv Biosciences Expands Leadership Team with New Chief Financial Officer and Chief Legal Officer
PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC, a global vertically integrated biopharmaceutical company, announced the appointment of Mandar Borkar as Global Chief Financial Officer (CFO) and Ross Oehler as Global Chief Legal Officer (CLO). “We are pleased to welcome Mandar Borkar and Ross Oehler to the management team,” said Chirag and Chintu Patel, Co-Founders of Kashiv BioSciences, “With two approved products on the market and a rapidly advancing pipeline, we are confident their.
Negative
Seeking Alpha
3 months ago
CFO: A Timing Methodology Failing For 10 Years
VictoryShares US 500 Enhanced Volatility Wtd ETF (CFO) combines low-volatility weighting with market timing. CFO's unconventional timing rules have reduced drawdown and volatility but result in lower risk-adjusted performance compared to SPY and CFA. CFO has significantly underperformed several low-volatility and market-timing ETFs, with PTLC showing much better market timing success.
Charts implemented using Lightweight Charts™